Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

NCT00790647 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: filgrastim
DRUG: bortezomib
DRUG: melphalan
PROCEDURE: Stem Cell Infusion

Sponsor

Boston Medical Center